Pain
September 1, 2024
Yang Zhou, Wanchen Sun, Yuxuan Fu et al.
9 citations
Moderate-to-severe acute postsurgical pain after spinal surgery can slow recovery. A combination of esketamine and pregabalin reduced the incidence of such pain from 60.5% to 27.3% in the first 48 hours after surgery, based on a randomized trial of 90 patients undergoing resection of spinal neoplasms. The odds ratio was 0.25, indicating a substantial benefit. However, mild dissociative symptoms occurred in 18.2% of the combination group versus none in the control group, suggesting the analgesic strategy carries this risk.
Pharmacological research
July 1, 2026
Yang Zhou, Wanchen Sun, Yuxuan Fu et al.
Among patients undergoing major surgery who had moderate-to-severe depressive symptoms before the operation, a single intraoperative dose of esketamine led to a higher rate of symptom remission three days after surgery compared with a placebo. In a randomized, double-blind trial of 435 patients, 28.3% in the esketamine group achieved remission versus 11.3% in the placebo group. Acute pain rates did not differ between groups. Esketamine treatment requires monitoring for possible dissociative side effects, and its clinical use for depressive symptoms should weigh benefits against risks.
Journal of neurosurgical anesthesiology
June 15, 2026
Yi Liang, Wanning Yang, Xinxin Wang et al.
In patients with prolonged disorders of consciousness, a one-hour intravenous infusion of esketamine (0.3 mg/kg/h) altered brain activity as measured by electroencephalography. The drug suppressed delta wave power while increasing beta and gamma wave power across the whole brain, and increased alpha wave power specifically in patients diagnosed as vegetative state/unresponsive wakefulness syndrome. Signal complexity, measured by Lempel-Ziv complexity, increased in the parietal and occipital brain regions. In minimally conscious patients, this complexity increase persisted for 30 minutes after the infusion stopped, while changes were transient in vegetative state patients. However, these neurophysiological changes were not accompanied by any improvements in behavioral responsiveness as assessed by the Coma Recovery Scale-Revised.